Demographic, clinical, and autoimmune profile among thrombocytopenic group and control group
| Cases | Controls | Odds ratio | 95% CI | |
|---|---|---|---|---|
| Results are shown as No (%) unless stated otherwise. | ||||
| *p = 0.009, estimated power 75%; †p = 0.029; ‡p = 0.009; §persistent proteinuria >0.5 g/day or cellular casts (red blood cell, haemoglobin, granular, tubular, mixed); ¶seizures, psychosis in the absence of offending drugs or metabolic rearrangements; **haemolytic anaemia with reticulocytosis and positive Coombs’ test. | ||||
| Demographic data | ||||
| Sex (F/M) | 47/3 | 94/6 | ||
| Age (years), mean (SD) | 27.4 (13.3) | 28.2 (12.5) | ||
| Time from diagnosis (years), mean (SD) | 11.7 (5.9) | 11.6 (5.6) | ||
| Clinical data | ||||
| ECLAM score median (min–max) | 3 (1–8) | 3 (0–7) | ||
| ECLAM ⩾4* | 19/50 (38) | 19/100 (19) | 2.61 | 1.13 to 5.96 |
| Malar rash | 23/50 (46) | 39/100 (39) | 1.33 | 0.63 to 2.79 |
| Discoid rash | 2/50 (4) | 1/100 (1) | 4.12 | 0.20 to 245.73 |
| Photosensitivity | 22/50 (44) | 37/100 (37) | 1.33 | 0.63 to 2.81 |
| Oral ulcers | 10/50 (20) | 28/100 (28) | 0.64 | 0.25 to 1.54 |
| Arthritis | 26/50 (52) | 60/100 (60) | 0.72 | 0.34 to 1.51 |
| Serositis | 7/50 (14) | 26/100 (26) | 0.46 | 0.15 to 1.22 |
| Renal disease§ | 10/50 (20) | 26/100 (26) | 0.71 | 0.27 to 1.71 |
| Neurological disorder¶ | 8/50 (16) | 17/100 (17) | 0.92 | 0.32 to 2.50 |
| Haemolytic anaemia** | 9/50 (18) | 17/100 (17) | 1.07 | 0.38 to 2.80 |
| Leucopenia (<4×109/l) | 26/50 (52) | 45/100 (45) | 1.32 | 0.53 to 2.76 |
| Antibody profile | ||||
| ANA | 50/50 (100) | 100/100 (100) | ||
| Anti-dsDNA | 28/50 (56) | 54/100 (54) | 1.08 | 0.51 to 2.2 |
| Anti-Sm | 5/50 (10) | 6/100 (6) | 1.74 | 0.39 to 7.22 |
| Anti-Ro(SSA) | 18/50 (36) | 31/100 (31) | 1.25 | 0.56 to 2.70 |
| Anti-La(SSB) | 6/50 (12) | 4/100 (4) | 3.27 | 0.72 to 16.44 |
| Anti-RNP | 10/50 (20) | 11/100 (11) | 2.02 | 0.70 to 5.70 |
| Anticardiolipin | 14/50 (28) | 20/100 (20) | 1.55 | 0.64 to 3.65 |
| IgG (>100 U) | 11/50 (22) | 16/100 (16) | ||
| IgM (>100 U) | 10/50 (20) | 11/100 (11) | ||
| Both | 7/50 (14) | 9/100 (9) | ||
| Complement activity† (low C3 or CH50) | 20/50 (40) | 22/100 (22) | 2.36 | 1.05 to 5.26 |
| Treatment‡ | ||||
| Low intensity | 26/48 (54) | 74/98 (76) | ||
| High intensity | 22/48 (46) | 24/98 (24) | ||